A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants With Moderately to Severely Active Crohn's Disease (CD)

Triple Combination Therapy in High Risk Crohn's Disease (CD)

Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis

Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study

Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144

Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment

An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease